

**Supplementary Table 1.** Criteria for Classifying Pathogenic Variants according to ACMG guidelines\*.

<b>Evidence of pathogenicity</b>	<b>Category</b>
<b>Very strong</b>	<b>PVS1</b> Null variant (nonsense, frameshift, canonical +/-1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease
	<b>PS1</b> Same amino acid change as a previously established pathogenic variant regardless of nucleotide change
<b>Strong</b>	<b>PS2</b> De novo (both maternity and paternity confirmed) in a patient with the disease and no family history
	<b>PS3</b> Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product
	<b>PS4</b> The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls
	<b>PM1</b> Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation
<b>Moderate</b>	<b>PM2</b> Absent from controls (or at extremely low frequency if recessive) in general population databases #
	<b>PM3</b> For recessive disorders, detected in trans with a pathogenic variant. This requires testing of parents (or offspring) to determine phase
	<b>PM4</b> Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants
	<b>PM5</b> Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before
	<b>PM6</b> Assumed de novo, but without confirmation of paternity and maternity
	<b>PP1</b> Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease
<b>Supporting</b>	<b>PP2</b> Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease
	<b>PP3</b> Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc)
	<b>PP4</b> Patient's phenotype or family history is highly specific for a disease with a single genetic etiology
	<b>PP5</b> Reputable source recently reports variant as pathogenic but the evidence is not available to the laboratory to perform an independent evaluation

The criteria selected to classify the variant c.900dup, p.(Glu301Argfs\*56) as pathogenic are shown in green. \* Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424.). # the variant c.900dup, p.(Glu301Argfs\*56) has not been described in gnomAD database (<https://gnomad.broadinstitute.org/>).